MarketPR
A $2.25 billion deal to acquire Precision Medicine Group puts McKesson's oncology and multi-speciality strategy in focus.
The US-based healthcare services provider will absorb Precision Medicine Group into that segment once regulatory approvals and other customary closing conditions are satisfied. The acquisition is a capacity buy.
Precision Medicine Group was founded as a global clinical research and commercialisation services provider and works with biotechnology and pharmaceutical companies.
Its integrated offerings combine services and technology-based products across biomarker intelligence, laboratory services, a global clinical research organisation, market access consulting, and commercialisation support.
Keep reading